Hamed Daghaghzadeh

Hamed Daghaghzadeh

Auto-generated profile, based on publicly available information

Hamed Daghaghzadeh

Integrative Functional Gastroenterology Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2016 in The American Journal of Clinical Nutrition
Verified
Journal Article
Closed access
PDF file
FHFahimeh Haghighatdoost
Fahimeh Haghighatdoost
LALeila Azadbakht
Leila Azadbakht
AKAmmar Hassanzadeh Keshteli
Ammar Hassanzadeh Keshteli
CFChristine Feinle-Bisset
Christine Feinle-Bisset
HDHamed Daghaghzadeh
Hamed Daghaghzadeh
PSPeyman Adibi Sedeh
Peyman Adibi Sedeh
Background: Potential associations between dietary glycemic index (GI) and glycemic load (GL) with psychological disorders remain uncertain.Objective:

1 August 2015 in Complementary Therapies in Clinical Practice
Verified
Journal Article
Closed access
MKMohammadali Kamali
Mohammadali Kamali
HTHamid Tavakoli
Hamid Tavakoli
MKMahmood Khodadoost
Mahmood Khodadoost
HDHamed Daghaghzadeh
Hamed Daghaghzadeh
MKMohammad Kamalinejad
Mohammad Kamalinejad
PAPayman Adibi
Payman Adibi

25 August 2022 in The Korean Journal of Gastroenterology
Verified
Journal Article
Open access
PDF file
PAPeyman Adibi
Peyman Adibi
MAMaryam Abdoli
Maryam Abdoli
HDHamed Daghaghzadeh
Hamed Daghaghzadeh
AKAmmar Hassanzadeh Keshteli
Ammar Hassanzadeh Keshteli
HAHamid Afshar
Hamid Afshar
AFAwat Feizi
Awat Feizi
Peyman Adibi, Maryam Abdoli, Hamed Daghaghzadeh, Ammar Hassanzadeh Keshteli, Hamid Afshar, Hamidreza Roohafza, Ahmad Esmaillzadeh and Awat Feizi. Korean J Gastroenterol 2022;80:77-84. https://doi.org/10.4166/kjg.2022.038

1 January 2016
Verified
Journal Article
Closed access
MMMasoud M Malekzadeh
Masoud M Malekzadeh
HVHomayoon Vahedi
Homayoon Vahedi
KGKimiya Gohari
Kimiya Gohari
PMParinaz Mehdipour
Parinaz Mehdipour
SSSadaf G. Sepanlou
Sadaf G. Sepanlou
RMReza Malekzadeh
Reza Malekzadeh

1 January 2015 in Journal of Research in Medical Sciences
Verified
Journal Article
Open access
PDF file
MSMohammad Reza Sharbafchi
Mohammad Reza Sharbafchi
HDHamed Daghaghzadeh
Hamed Daghaghzadeh
FNFateme Naji
Fateme Naji
HAHamid Afshar
Hamid Afshar
AFAwat Feizi
Awat Feizi
HTHamid Tavakoli
Hamid Tavakoli
Background: Treating inflammatory bowel disease (IBD) with antidepressants might be of utility to improve patient's condition. The aim of this study was to assess the efficacy of Duloxetine on depression, anxiety, severity of symptoms, and quality of life (QOL) in IBD patients. Materials and Methods: In a randomized, double-blind, controlled clinical trial on 2013-2014, in Alzahra Hospital (Isfahan, Iran), 44 IBD patients were chosen to receive either duloxetine (60 mg/day) or placebo. They were treated in a 12 weeks program, and all of the participants also received mesalazine, 2-4 g daily. We assessed anxiety and depression with Hospital Anxiety and Depression Scale, the severity of symptoms with Lichtiger Colitis Activity Index and QOL with World Health Organization Quality of Life Instruments, before and just after the treatment. The data were analyzed using Paired sample t-test and ANCOVA. Results: In 35 subjects who completed the study, the mean (standard error [SE]) scores of depression and anxiety were reduced in duloxetine more than placebo group, significantly (P = 0.041 and P = 0.049, respectively). The mean (SE) scores of severity of symptom were also reduced in duloxetine more than the placebo group, significantly (P = 0.02). The mean (SE) scores of physical, psychological, and social dimensions of QOL were increased after treatment with duloxetine more than placebo group, significantly (P = 0.001, P = 0.038, and P = 0.015, respectively). The environmental QOL was not increased significantly (P = 0.260). Conclusion: Duloxetine is probably effective and safe for reducing depression, anxiety and severity of physical symptoms. It also could increase physical, psychological, and social QOL in patients.

1 January 2015 in Journal of Research in Medical Sciences
Verified
Journal Article
Open access
PDF file
HAHamid Afshar
Hamid Afshar
MTMahshid Tabatabaeian
Mahshid Tabatabaeian
HRHamidreza Roohafza
Hamidreza Roohafza
HDHamed Daghaghzadeh
Hamed Daghaghzadeh
AFAwat Feizi
Awat Feizi
PSPeyman Adibi Sedeh
Peyman Adibi Sedeh
Background: Psychological profile of inflammatory bowel disease patients is not well studied in Iran. We investigated the psychological status of Iranian patients with ulcerative colitis (UC) and its relationship with disease activity and quality of life (QOL). Materials and Methods: A cross-sectional study was conducted on adult UC patients. The Lichtiger Colitis Activity Index, Hospital Anxiety and Depression Scale, General Health Questionnaire-12, and WHOQOL-BREF, were completed by the patients. Results: From 120 studied patients, 35 (29.2%), 48 (40.0%), and 46 (38.3%) had significant anxiety, depression, and psychological distress, respectively. Anxiety, depression, and psychological distress were strongly correlated with disease activity (r = 0.357 to 0.439, P < 0.01). Disease activity was negatively correlated with all QOL dimensions (r = −0.245 to −0.550, P < 0.01). Anxiety, depression, and psychological distress were also negatively correlated with all QOL domains (r = −0.356 to −0.789, P < 0.01). In the regression models, anxiety was independently associated with active disease (β = 4.150, P = 0.049). Furthermore, disease activity was associated with the physical health (β = −0.371, P < 0.001). For almost all of the QOL domains, depression and psychological distress were independent predictors (β = −0.296 to −0.453, P < 0.001). Conclusion: Anxiety, depression, and psychological distress are highly frequent in UC patients of our society and are strongly associated with disease activity. Depression and psychological distress are important predictors of poor QOL in these patients. Further prospective studies, as well as clinical trials, are warranted in this regard.